Reflux esophagitis
Conditions
Interventions
Vonoprazan 20mg orally once a day for 4 weeks
Esomeprazole 20mg orally once a day for 4 weeks
Sponsors
Department of Gastroenterology, Sapporo-kosei General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients aged 20 years or older at the time of providing informed consent 2.Patients who are diagnosed as having reflux esophagitis by physician 3.Patients who check 2-3days or 4-7 days a week in GerdQ Q1 and/or Q2
Exclusion criteria
Exclusion criteria: 1.Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia), and sudden weight loss 2.Patients confirmed or suspected malignant lesion 3.Patients with a history of gastrointestinal resection or vagotomy 4.Patients in Irritable Bowel Syndrome 5.Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease. 6.Women who are pregnant or who may possibly be pregnant, and lactating mothers 7.Other patients whom the investigator considers unsuitable for admission to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gerd Q total score of heartburn and acid regurgitation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Gerd Q each score of heartburn and acid regurgitation 2.Gerd Q each score of epigastralgia, nausea and vomiting 3.Evaluation of treatment response with Gerd Q | — |
Countries
Japan
Contacts
Public ContactYohei Terakado
Sapporo-kosei General Hospital Department of Gastroenterology
Outcome results
None listed